Die Inhalte stammen aus dem NEJM Journal Watch Oncology & Hematology, der von der NEJM Group, a Division of the Massachusetts Medical Society, hergestellt und veröffentlich wird. Alle Rechte sind vorbehalten und alle Inhalte sind urheberrechtlich geschützt. Universimed und unsere Sponsoren ermöglichen Ihnen den Zugang zu diesen Inhalten als professionelle Unterstützung.
A Next-Generation FGR2 Inhibitor for Intrahepatic Cholangiocarcinoma
Patients with advanced disease and FGFR2 alterations treated with the FGFR2 inhibitor futibatinib had a 42% response rate.
Opioid Use for Patients with Cancer
A new guideline includes 13 recommendations, but most of them reflect expert consensus rather than hard evidence.
KRAS G12C Inhibitor Shows Modest Activity in Pancreatic Cancer
Response to treatment with the KRAS G12C inhibitor sotorasib was seen in 21% of patients with advanced KRAS p.G12C-mutated pancreatic cancer.
Cognitive Impairment in Patients with Early-Stage Breast Cancer
Impairment was greater in patients than controls, but declines in some cognitive domains abated over time.
Colorectal Neoplasia Prevalence at ≥10-Year Follow-Up Screening Colonoscopy
Prevalence of advanced neoplasm was much lower at repeat screening colonoscopies than at all screening colonoscopies.
Mitigating Vasomotor Symptoms from Adjuvant Endocrine Therapy
A novel nonhormonal oral treatment shows promise.
Gemcitabine/Nab-Paclitaxel Fails to Best Adjuvant Gemcitabine in Pancreatic Cancer
Centrally assessed disease-free survival was similar with gemcitabine alone and gemcitabine/nab-paclitaxel combined.
Olaparib Effective Maintenance Therapy for Germline BRCA-Mutated Pancreatic Cancer
Progression-free survival and other outcomes favored olaparib over placebo in updated results from the POLO trial.
Adagrasib Shows Promise in Colorectal Cancer with KRAS G12C Mutation
Response was seen in heavily pretreated patients receiving adagrasib alone or combined with cetuximab.